The ATPAF1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the ATPAF1 gene in the human HAP1 cell line. This product provides a heterogeneous pool of cells carrying targeted gene disruption, enabling functional studies of ATPAF1 without clonal isolation. ATPAF1 encodes a critical assembly factor for mitochondrial ATP synthase (Complex V), and its inactivation serves as a loss-of-function model for investigating oxidative phosphorylation defects.
HAP1 is a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia line. It exhibits an adherent, fibroblast-like morphology and retains a haploid genetic background for most chromosomes, making it particularly amenable to knockout studies due to the requirement of disrupting only a single allele. The leukemic origin of HAP1 also provides a context for studying metabolic adaptations in cancer cells, where mitochondrial function is often altered.
ATPAF1 (ATP synthase mitochondrial F1 complex assembly factor 1) functions as a dedicated chaperone for the F1 component of ATP synthase. It interacts transiently with ATPAF2 and stabilizes assembly intermediates containing the subunits ATP5F1A, ATP5F1B, and ATP5F1C. Through this chaperone activity, ATPAF1 ensures proper folding and incorporation of F1 subunits, enabling the formation of functional Complex V. Disruption of ATPAF1 abrogates ATP synthase assembly, leading to dissipation of mitochondrial membrane potential and diminished ATP synthesis. Upstream regulatory factors including PGC-1??, NRF1, and TFAM control mitochondrial biogenesis and oxidative phosphorylation gene expression, thereby influencing ATPAF1 transcription. Downstream, loss of ATPAF1 impairs electron transport chain efficiency and disrupts cellular energy homeostasis, linking it to mitochondrial diseases such as complex V deficiency.
In the haploid HAP1 background, ATPAF1 knockout provides a clean genetic model for dissecting the assembly pathway of ATP synthase. The leukemic origin further allows exploration of how mitochondrial dysfunction intersects with cancer metabolism, particularly in cells reliant on oxidative phosphorylation. This model is relevant to research on mitochondrial complex V deficiency disorders, neurodegenerative conditions associated with ATP synthase defects, and metabolic disorders stemming from impaired oxidative phosphorylation. The polyclonal nature of the population preserves biological variability while maintaining robust target-gene disruption, making it suitable for pooled functional screens and heterogeneous disease modeling.
This product is intended for mitochondrial biology and drug discovery. Researchers can model mitochondrial disease, screen for molecules that rescue ATP synthase assembly, and assess bioenergetics via Seahorse XF analysis or ATP luminescence. It also supports mitochondrial biogenesis studies and drug toxicity screening related to mitochondrial impairment. Routine characterization uses western blotting for ATP synthase subunits, blue native PAGE for complex V, and immunofluorescence for mitochondrial membrane potential. For further details, please contact Ascent Research.
